Noxopharm Ltd has released a press release.
Durable Anti-Cancer Effect Confirmed in DARRT-1 Study
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Noxopharm
- Potential Fundamental Change in Treatment of Brain Cancer
- Further Review Shows Major Clinical Benefits from Veyonda
- Veyonda and Radiotherapy Profiled at Key Oncology Meeting
- Appendix 4E and Audited Financial Statements FY19
- More Evidence that Veyonda Enhances RT in Prostate Cancer
Later from Noxopharm
- Dr Graham Kelly to Assume CEO Role
- Appendix 4C - Quarterly
- Noxopharm Announces Appointment of Chief Commercial Officer
- Lodgement of Nyrada Inc Prospectus - Initial Public Offering
- Positive DARRT-1 Data in Late-Stage Prostate Cancer
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm